TY - JOUR
T1 - Associations between alcohol use disorder polygenic score and remission in participants from high-risk families and the Indiana Biobank
AU - Lai, Dongbing
AU - Kuo, Sally I.Chun
AU - Wetherill, Leah
AU - Aliev, Fazil
AU - Zhang, Michael
AU - Marco, Abreu
AU - Schwantes-An, Tae Hwi
AU - Dick, Danielle
AU - Francis, Meredith W.
AU - Johnson, Emma C.
AU - Kamarajan, Chella
AU - Kinreich, Sivan
AU - Kuperman, Samuel
AU - Meyers, Jacquelyn
AU - Nurnberger, John I.
AU - Liu, Yunlong
AU - Edenberg, Howard J.
AU - Porjesz, Bernice
AU - Agrawal, Arpana
AU - Foroud, Tatiana
AU - Schuckit, Marc
AU - Plawecki, Martin H.
AU - Bucholz, Kathleen K.
AU - McCutcheon, Vivia V.
N1 - Publisher Copyright:
© 2023 The Authors. Alcohol: Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.
PY - 2024/2
Y1 - 2024/2
N2 - Background: In the United States, ~50% of individuals who meet criteria for alcohol use disorder (AUD) during their lifetimes do not remit. We previously reported that a polygenic score for AUD (PGSAUD) was positively associated with AUD severity as measured by DSM-5 lifetime criterion count, and AUD severity was negatively associated with remission. Thus, we hypothesized that PGSAUD would be negatively associated with remission. Methods: Individuals of European (EA) and African ancestry (AA) from the Collaborative Study on the Genetics of Alcoholism (COGA) who met lifetime criteria for AUD, and two EA cohorts ascertained for studies of liver diseases and substance use disorders from the Indiana Biobank were included. In COGA, 12-month remission was defined as any period of ≥12 consecutive months without meeting AUD criteria except craving and was further categorized as abstinent and non-abstinent. In the Indiana Biobank, remission was defined based on ICD codes and could not be further distinguished as abstinent or non-abstinent. Sex and age were included as covariates. COGA analyses included additional adjustment for AUD severity, family history of remission, and AUD treatment history. Results: In COGA EA, PGSAUD was negatively associated with 12-month and non-abstinent remission (p ≤ 0.013, βs between −0.15 and −0.10) after adjusting for all covariates. In contrast to the COGA findings, PGSAUD was positively associated with remission (p = 0.004, β = 0.28) in the Indiana Biobank liver diseases cohort but not in the Indiana Biobank substance use disorder cohort (p = 0.17, β = 0.15). Conclusions: PGSAUD was negatively associated with 12-month and non-abstinent remission in COGA EA, independent of behavioral measures of AUD severity and family history of remission. The discrepant results in COGA and the Indiana Biobank could reflect different ascertainment strategies: the Indiana Biobank participants were older and had higher rates of liver disease, suggesting that these individuals remitted due to alcohol-related health conditions that manifested in later life.
AB - Background: In the United States, ~50% of individuals who meet criteria for alcohol use disorder (AUD) during their lifetimes do not remit. We previously reported that a polygenic score for AUD (PGSAUD) was positively associated with AUD severity as measured by DSM-5 lifetime criterion count, and AUD severity was negatively associated with remission. Thus, we hypothesized that PGSAUD would be negatively associated with remission. Methods: Individuals of European (EA) and African ancestry (AA) from the Collaborative Study on the Genetics of Alcoholism (COGA) who met lifetime criteria for AUD, and two EA cohorts ascertained for studies of liver diseases and substance use disorders from the Indiana Biobank were included. In COGA, 12-month remission was defined as any period of ≥12 consecutive months without meeting AUD criteria except craving and was further categorized as abstinent and non-abstinent. In the Indiana Biobank, remission was defined based on ICD codes and could not be further distinguished as abstinent or non-abstinent. Sex and age were included as covariates. COGA analyses included additional adjustment for AUD severity, family history of remission, and AUD treatment history. Results: In COGA EA, PGSAUD was negatively associated with 12-month and non-abstinent remission (p ≤ 0.013, βs between −0.15 and −0.10) after adjusting for all covariates. In contrast to the COGA findings, PGSAUD was positively associated with remission (p = 0.004, β = 0.28) in the Indiana Biobank liver diseases cohort but not in the Indiana Biobank substance use disorder cohort (p = 0.17, β = 0.15). Conclusions: PGSAUD was negatively associated with 12-month and non-abstinent remission in COGA EA, independent of behavioral measures of AUD severity and family history of remission. The discrepant results in COGA and the Indiana Biobank could reflect different ascertainment strategies: the Indiana Biobank participants were older and had higher rates of liver disease, suggesting that these individuals remitted due to alcohol-related health conditions that manifested in later life.
KW - alcohol use disorder severity
KW - alcohol use disorder treatment history
KW - family history of remission
KW - polygenic score
KW - remission
UR - http://www.scopus.com/inward/record.url?scp=85179373434&partnerID=8YFLogxK
U2 - 10.1111/acer.15239
DO - 10.1111/acer.15239
M3 - Article
C2 - 38054532
AN - SCOPUS:85179373434
SN - 2993-7175
VL - 48
SP - 283
EP - 294
JO - Alcohol: Clinical and Experimental Research
JF - Alcohol: Clinical and Experimental Research
IS - 2
ER -